Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, Randomized, Placebo-controlled Study on Efficacy, Safety and Tolerability of Ancrod in Patients With Sudden Sensorineural Hearing Loss (SSHL)

Trial Profile

Double-blind, Randomized, Placebo-controlled Study on Efficacy, Safety and Tolerability of Ancrod in Patients With Sudden Sensorineural Hearing Loss (SSHL)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ancrod (Primary) ; Ancrod (Primary)
  • Indications Sensorineural hearing loss; Sudden hearing loss
  • Focus Therapeutic Use
  • Sponsors Nordmark Arzneimittel
  • Most Recent Events

    • 20 Dec 2018 Status changed from active, no longer recruiting to completed.
    • 12 Oct 2018 This trial has been changed to Completed in Czech Republic (End date: 2018-09-18), according to European Clinical Trials Database.
    • 25 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top